Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05

被引:52
作者
Feigenberg, SJ
Lee, WR
Desilvio, ML
Winter, K
Pisansky, TM
Bruner, DW
Lawton, C
Morton, G
Baikadi, M
Sandler, H
机构
[1] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, Winston Salem, NC USA
[3] Amer Coll Radiol, RTOG Stat Dept, Philadelphia, PA USA
[4] Mayo Clin, Coll Med, Div Radiat Oncol, Rochester, MN USA
[5] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA
[6] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[7] NE Radiat Oncol Ctr, Scranton, PA USA
[8] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 62卷 / 04期
关键词
prostate cancer; brachytherapy; quality of life;
D O I
10.1016/j.ijrobp.2004.12.061
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To prospectively assess health-related quality of life (HRQOL) during the first year after treatment with prostate brachytherapy (PB) alone for T1c-2a prostate cancer. Materials and Methods: Ninety-eight patients from 24 institutions were eligible and properly entered on this study. All patients were treated with PB alone using I-125 (Oncura Model 6711). The prescription dose was 145 Gy. Three separate health-related quality of life questionnaires (HRQOL) (Functional Assessment of Cancer Therapy-Prostate [FACT-P], Sexual Adjustment Questionnaire [SAQ], and International Prostate Symptom Score [IPSS]) were self-administered before and after PB (baseline; 3, 6, 9, and 12 months after PB). The standard error of the mean (SEM) was used to analyze changes in HRQOL scores over time. Patients who improved greater than the SEM were categorized as improved; patients that declined greater than the SEM were categorized as declined; patients were otherwise categorized as stable. All changes are measured using the pretreatment HRQOL score as baseline. Results: The percentage of men who reported the ability to have an erection decreased from 73% at baseline (65% unassisted, 8% assisted) to 57% at 1 year (36% unassisted, 21% assisted). The rate of urinary incontinence increased to 14% at 6 months but had decreased to 1% at the 12-month follow-up. At 1 year after P13, 80% of men reported decreased sexual functioning according to SAQ scores. More than 60% of men reported decreased urinary function at 12 months compared with baseline. Conclusions: This article represents the first prospective, multi-institutional study of HRQOL in men treated with PB and demonstrates that patients undergoing PB have a very high overall HRQOL. The rate of incontinence by 1 year after PB is low, but many patients continue to have obstructive symptoms at I year. Although 78% of 1-year respondents state that they can achieve an erection with or without assistance, almost 50% report a decrease in sexual function. (c) 2005 Elsevier Inc.
引用
收藏
页码:956 / 964
页数:9
相关论文
共 37 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
[Anonymous], QUALITY LIFE PHARMAC
[3]   The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer [J].
Bacon, CG ;
Giovannucci, E ;
Testa, M ;
Kawachi, I .
JOURNAL OF UROLOGY, 2001, 166 (05) :1804-1810
[4]   Quality of life outcomes after brachytherapy for early stage prostate cancer [J].
Brandeis, JM ;
Litwin, MS ;
Burnison, CM ;
Reiter, RE .
JOURNAL OF UROLOGY, 2000, 163 (03) :851-857
[5]  
Bruner DW, 1998, INT J RADIAT ONCOL, V42, P202
[6]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[7]  
Cohen J, 1988, ANAL BEHAV SCI
[8]   The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management [J].
Cooperberg, MR ;
Lubeck, DP ;
Meni, MV ;
Mehta, SS ;
Carroll, PR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2141-2149
[9]  
D'Amico AV, 1999, CANCER, V86, P1632, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1632::AID-CNCR2>3.0.CO
[10]  
2-5